Zdrowie i gospodarka · 21/05/2001

FDA Seeks Public Comments on Intersection of 180-Day Generic Drug Exclusivity and Pediatric Exclusivity

The FDA is requesting public input on its interpretation of the Federal Food, Drug, and Cosmetic Act provisions related to the overlap of 180-day generic drug exclusivity and pediatric exclusivity, as inquiries have raised questions about this intersection.